NIRAMAI Health Analytix

NIRAMAI Health Analytix is a health-tech company headquartered in Bangalore, India, developing artificial-intelligence-based screening for early-stage breast cancer. It addresses the problem that mammography is costly, radiation-based, and often inaccessible outside major hospitals, leaving many women in low-resource settings without regular screening.

Its flagship product, Thermalytix, analyzes high-resolution thermal images of the breast with AI algorithms to flag abnormalities without radiation or physical contact, offered alongside the portable Niramai SMILE-100 imaging device and the Mythri mobile screening service. Clinics, hospitals, and corporate wellness programs across more than 22 countries use the system, which the company says has screened over 500,000 women and is backed by more than 40 patents.

1. Thermalytix analysis: Uses AI to detect breast abnormalities from thermal images without radiation.

2. Niramai SMILE-100: Portable thermal-imaging hardware certified for clinical use.

3. Mythri screening service: Brings mobile breast-screening camps to underserved communities.

4. Non-invasive procedure: Requires no compression or contact, suitable for women aged 18 to 80+.

5. Low-cost screening: Priced at roughly 10-20% of traditional mammography screening.

6. Global deployment: Deployed in more than 22 countries, screening over 500,000 women to date.